4basebio PLC announced a product supply agreement with Neomatrix. Under the agreement, 4basebio will supply clinical and preclinical DNA materials into Neomatrix' neoantigen cancer vaccine program. The program is expected to start patient enrolment in early 2024.

Neomatrix will gain access to 4basebio's proprietary DNA products including hpDNA™? and oeDNA. 4basebio will manufacture and provide the personalised clinical grade DNA products, the key component in Neomatrix' immunotherapy cancer treatment.

Neomatrix' vaccine based cancer treatment utilises the patient's immune system to recognise newly generated synthetic DNA (neoantigens), created by and displayed on tumour cells. Personalised cancer vaccines require a tumour biopsy which is sequenced to identify the neoantigens created by cancer-specific DNA mutations. A patient specific DNA sequence coding for such neoantigens is then designed, produced and administered.

The time between initial biopsy and vaccine administration ("needle to needle") is critical. 4basebio's enzymatically produced synthetic DNA, with its rapid manufacturing timescales, is uniquely positioned to provide high performant DNA products in a timely fashion.